Myasthenic crisis

Current Treatment Options in Neurology

Volumn 6, Issue 1, 2004, Pages 3-15

  Kirmani, Jawad F ^a   Yahia, Abutaher M ^b   Qureshi, Adnan I ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ATROPINE; AZATHIOPRINE; CHICKENPOX VACCINE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LIDOCAINE; LOPERAMIDE; MAGNESIUM; MEASLES VACCINE; MUMPS VACCINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENOBARBITAL; PHENYTOIN; PREDNISONE; PROCAINAMIDE; PROPANTHELINE BROMIDE; PYRIDOSTIGMINE; QUINIDINE; RIFAMPICIN; RUBELLA VACCINE; STEROID; SUXAMETHONIUM; UNINDEXED DRUG;

ABDOMINAL CRAMP; ACHILLES TENDON RUPTURE; ADRENAL CORTEX INSUFFICIENCY; ARTIFICIAL VENTILATION; ASEPTIC NECROSIS; ASPIRATION PNEUMONIA; AUTONOMIC NEUROPATHY; BRAIN PSEUDOTUMOR; BREATHING MUSCLE; CARBOHYDRATE TOLERANCE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONVULSION; COST EFFECTIVENESS ANALYSIS; CUSHINGOID SYNDROME; DIARRHEA; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; ENDOTRACHEAL INTUBATION; ENDOTRACHEAL TUBE; FEVER; FLUID RETENTION; GINGIVA HYPERPLASIA; HEADACHE; HEART ARRHYTHMIA; HIRSUTISM; HISTORY OF MEDICINE; HUMAN; HYPERTENSION; HYPERVOLEMIA; HYPOKALEMIC ALKALOSIS; HYPOPHYSIS DISEASE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IMPAIRED GLUCOSE TOLERANCE; INDIVIDUALIZATION; INFECTION; INSPIRATORY CAPACITY; INTENSIVE CARE UNIT; INTRACRANIAL HYPERTENSION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LEUKOPENIA; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MENSTRUATION DISORDER; MUSCLE MASS; MUSCLE WEAKNESS; MYALGIA; MYASTHENIA GRAVIS; MYOPATHY; NASOGASTRIC TUBE; NAUSEA; NAUSEA AND VOMITING; NEUROMUSCULAR JUNCTION DISORDER; OSTEOPOROSIS; PAPILLEDEMA; PATHOLOGIC FRACTURE; PEPTIC ULCER; PLASMAPHERESIS; POTASSIUM DEPLETION; PROGNOSIS; RESPIRATORY FAILURE; REVIEW; RISK REDUCTION; SALIVATION DISORDER; SEPSIS; SIDE EFFECT; SODIUM RETENTION; STOMACH HEMORRHAGE; STOMACH PERFORATION; TENDON RUPTURE; THYMECTOMY; TREATMENT PLANNING; TREMOR; VERTEBRA FRACTURE; VERTIGO; VITAL CAPACITY; VOMITING; WOUND HEALING IMPAIRMENT;

EID: 3142691094     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-004-0034-3     Document Type: Review

References (20)

1. Fink ME: Treatment of the critically ill patient with myasthenia gravis. In Neurological and Neurosurgical Intensive Care, edn 3. Edited by Ropper AH. New York: Raven Press; 1993:351-362.
2. Wilks S: On cerebritis, hysteria, and bulbar paralysis, as illustrative of arrest of function of the cerebrospinal centers. Guy's Hospital Report 1877, 22:7-55.
3. Pascuzzi RM: The history of myasthenia gravis. Neurol Clin 1994, 12:231-242.
4. Drachman DB: Myasthenia gravis. N Engl J Med 1994, 330:1797.
5. Phillips LH II: The epidemiology of myasthenia gravis. Neurol Clin 1994, 12:263-271.
6. Bedlack RS, Sanders DB: How to handle myasthenic crisis: essential steps in-patient care. Postgrad Med 2000, 107:211-214.
7. Mayer S: Intensive care of the myasthenic patient. Neurology 1997, 48:70S-75S.
8. Berrouschot J, Baumann I, Kalischewski P, et al.: Therapy of myasthenic crisis. Crit Care Med 1997, 25:1228-1235.
9. Thomas CE, Mayer SA, Gungor Y, et al.: Myasthenic crisis: clinical features, mortality, complications and risk factors for prolonged intubation. Neurology 1997, 48:1253-1260.
10. Qureshi AI, Bhardwaj A, Ulatowski JA: Neurocritical care for the house officer. In ICU Care-House Officer Series. Edited by Helfaer M. Baltimore: Williams & Wilkins; 1998:65-92.
11. Younger DS, Raksadawan N: Therapy in neuromuscular disease. Neurol Clin 2001, 19:205-215.
12. Mayer SA, Thomas CE: Therapy of myasthenic crisis [letter; comment]. Crit Care Med 1998, 26:1136-1137.
13. London SF, Ringel SP: Neuromuscular emergencies. In Emergent and Urgent Neurology. Edited by Weiner WJ. Philadelphia: JB Lippincott; 1992:59-78.
14. Rieder P, Louis M, Jolliet P, et al.: The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis. Intensive Care Med 1995, 21:663-668.
15. Qureshi AI, Suri MF: Plasma exchange for treatment of myasthenia gravis: pathophysiologic basis and clinical experience. Ther Apher 2000, 4:280-286.
16. Qureshi AI, Choudhry MA, Akbar MS, et al.: Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999, 52:629-632.
17. Gajdos P, Chevret S, Clair B, et al.: Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997, 41:789-796.
18. Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD: Myasthenic crisis: response to plasmapheresis following failure of intravenous gamma globulin. Arch Neurol 1993, 50:837-840.
19. Kissel JT, Franklin GM: Treatment of myasthenia gravis: a call to arms [letter; comment]. Neurology 2000, 55:3-4.
20. Cohen MS, Younger D: Aspects of the natural history of myasthenia gravis: crisis and death. Ann N Y Acad Sci 1981, 377:670-677.